Descripción de la empresa
IM Cannabis Corp. operates within the healthcare sector, specifically classified under the drug manufacturing industry for specialty and generic pharmaceuticals, where it focuses on the cultivation and distribution of medical cannabis products. The company's core business involves the breeding, growing, and supply of medical cannabis dried flowers and extracts for patients in Israel and Germany, utilizing brands such as IMC, BLKMT, WAGNERS, and LOT420. As of the latest data, the enterprise holds a market capitalization of $2.16 million and reports trailing twelve-month revenue of $54.73 million, while the specific count of employees is not disclosed in available records. These financial figures indicate a small-cap entity operating with a substantial revenue base relative to its valuation, suggesting a business model that generates significant top-line sales despite the lack of traditional profitability metrics typically associated with mature pharmaceutical firms.
Salud financiera
The company reported total revenue of $54.73 million over the trailing twelve months, yet this income resulted in a net loss of $11.319 million and an EBITDA of -$4.559 million, revealing a cost structure where expenses significantly outpace gross earnings before interest, taxes, depreciation, and amortization. This divergence between revenue and net income highlights aggressive operating expenditures or significant one-time costs that are not fully offset by the 17.7% gross margin achieved from sales. Furthermore, the free cash flow stands at -$431,875, indicating a negative cash generation capability that constrains the company's financial flexibility and limits its ability to fund operations or capital expenditures without external financing. The margin profile presents a mixed picture with a gross margin of 17.7%, an operating margin of -31.4%, and a profit margin of -20.7%, demonstrating that while production costs are controlled to some degree, overhead and operational inefficiencies severely impact overall profitability. On the balance sheet, the company holds $2.73 million in cash against $16.27 million in debt, creating a net debt position that implies a highly leveraged financial structure rather than a conservative, cash-rich stance. Additionally, the debt-to-equity ratio is not disclosed, preventing a precise leverage calculation, but the cash-debt disparity suggests reliance on debt financing to sustain current operations. Liquidity concerns are evident given a current ratio of 0.67, which indicates that the company's current assets are insufficient to cover its current liabilities, pointing to potential short-term solvency challenges. Return on Equity and Return on Assets are not available for calculation due to the loss-making status, but the reported Return on Assets of -10.9% confirms that the company is currently destroying value on its asset base rather than generating returns for shareholders.
Evaluación de valoración
The valuation metrics for IM Cannabis Corp. reflect its unprofitable status, with a trailing P/E ratio of N/A and a forward P/E of -0.27, a negative figure that implies the market expects earnings to remain negative or that the forward estimate is a loss that is being priced against current equity. The price-to-book ratio stands at -0.76, indicating that the stock trades at a negative premium relative to its book value, a situation common for distressed or loss-making entities where the market price is below the accounting value of net assets. Alternative valuation multiples provide further insight, with a price-to-sales ratio of 0.04 and an EV/EBITDA of -3.47, suggesting the market values the company primarily on its revenue generation rather than earnings power, as sales are the only positive metric in the multiple analysis. Regarding price volatility and positioning, the stock has traded between a 52-week low of $0.29 and a 52-week high of $7.12, with the current market price of $2.16 million market cap implying a trading level that sits approximately 69.7% below the 52-week high and roughly 645% above the 52-week low. The beta of 2.27 signifies that the stock's price is highly volatile, moving with more than double the magnitude of the broader market index, which increases the risk profile for investors sensitive to market fluctuations.
Growth & Income
IM Cannabis Corp. demonstrates robust top-line expansion with a year-over-year revenue growth rate of 17.6%, whereas earnings growth is N/A due to the company's continued losses, implying that revenue expansion is not yet translating into profitability at this stage. The company does not distribute dividends to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means that all available cash flows are theoretically available for reinvestment or debt repayment rather than income distribution. This non-dividend policy aligns with the capital allocation strategy of growth-stage biotech or cannabis firms that prioritize funding operations and expansion over returning capital to investors. Consequently, the overall growth and income profile is characterized by strong revenue momentum coupled with a complete absence of current income generation, reflecting a high-risk, high-potential growth trajectory where value creation is deferred to future operational efficiency improvements.